Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norwegian Prednisolone in Early Psychosis Study
2017-000163-32Phase 2Terminated
- Sponsor
- Helse Bergen
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia, schizophreniform disorder, schizoaffective disorder and 1 more comparing Prednisolone plus antipsychotic medication with Placebo plus antipsychotic medication (2 arms). Primary endpoint: Change in PANSS total score over 6 weeks. Started Feb 2017; status: terminated.
02
Drugs
prednisolone
03
Conditions
schizophreniaschizophreniform disorderschizoaffective disorderSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2017-000163-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000163-32.